Biventricular Support With Intracorporeal, Continuous Flow, Centrifugal Ventricular Assist Devices. Journal Article

Local Library Link: Find It @ Loyola

Authors: Arabía, FA; Milano, CA; Mahr, C; McGee, EC; Mokadam, NA; Rame, JE; Moriguchi, JD; Ramzy, D; Naftel, DC; Myers, SL; Kirklin, JK
Article Title: Biventricular Support With Intracorporeal, Continuous Flow, Centrifugal Ventricular Assist Devices.
Abstract: BACKGROUND: The incidence of right ventricular dysfunction requiring right ventricular assist device after left ventricular assist device placement has been reported between 10% to 30%. The mortality rate is higher compared with patients who require left ventricular assist device only; the most effective and safest biventricular assist device remains unknown. We aimed to determine the survival outcomes and frequency of adverse events in patients with two durable, intracorporeal, continuous flow centrifugal pumps for support. METHODS: Between November 2012 and June 2015, 38 patients were identified from INTERMACS received durable, intracorporeal continuous flow centrifugal pumps for biventricular support. Pediatric patients were excluded. Mean age was 47 years, and 74% of patients were male. The common primary diagnoses in this cohort were dilated myopathy, idiopathic (37%) and ischemic (16%). RESULTS: Nineteen participating centers implanted devices in 38 patients; 11 patients died with device in place, 9 patients received a heart transplant, and 18 were alive on support with the right ventricular assist device in place. Survival outcomes were 68% at 6 months and 62% at 12 months. The left ventricular assist device was placed in the left ventricle apex in 91% of cases, and in 9%, the location was not specified. The right ventricular assist device was placed in the right ventricle in 50%, right atrium in 37%, and not specified in 13%. The adverse events included infection 50%, bleeding 44%, respiratory failure 31.6%, and malfunction 26.3%; neurologic dysfunction 26.3%; renal dysfunction 18.4%; and arrhythmia 18.4%. CONCLUSIONS: The use of durable, intracorporeal, continuous flow centrifugal pumps for management of advanced biventricular heart failure is associated with high morbidity and mortality. Further investigation of this device configuration is warranted.
Journal Title: The Annals of Thoracic Surgery
ISSN: 1552-6259; 0003-4975
Publisher: Unknown  
Date Published: 2018
LUC Authors
  1. Edwin McGee, Jr.
    21 McGee
Related LUC Article